Inozyme Pharma Investor Relations Material

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases that affect the vasculature, soft tissue, and skeleton. The company's research is centered on disorders related to the PPi-Adenosine Axis, a pathway crucial for mineralization and vascular health. Disruptions in this pathway can lead to severe conditions such as ENPP1 and ABCC6 deficiencies, which Inozyme targets with its lead product candidate, INZ-701. This enzyme replacement therapy is designed to address pathologic mineralization and intimal proliferation, aiming to reduce the morbidity and mortality associated with these conditions. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.